Danisco Venture has made a strategic investment in the US start-up company WellGen Inc. The New Jersey-based company is developing proprietary disease prevention products for the human food, pet-food, dietary supplement, and human therapeutic markets. WellGen´s biotechnology-based technical platform is screening the effect of food and related substances on the expression of genes associated with human disease. WellGen is developing proprietary substances that, if successful, will contribute to reducing the risk of certain types of cancer.